Glenmark Pharmaceuticals gets tentative approval of Saxagliptin Tablets
From USFDA
Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB.According to IMS Health sales data for the 12 month period ending April 2017, the Onglyza Tablets, 2.5 mg and 5 mg market1 achieved annual sales of approximately $518.5 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content